- In March 2025, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. announced the launch of its next-generation ANA testing platform in the Asia-Pacific region, designed to improve test accuracy and throughput. The new system integrates advanced automation and artificial intelligence to provide rapid, reliable results for autoimmune disease diagnosis, supporting faster clinical decision-making
- In February 2025, Sysmex Corporation, a leading Japanese diagnostics company, unveiled its enhanced ELISA platform for ANA testing, featuring increased sensitivity and precision. This development aims to address the growing demand for accurate autoimmune diagnostics in the Asia-Pacific market, driven by rising awareness of autoimmune diseases and expanding healthcare infrastructure
- In January 2025, Bio-Rad Laboratories, Inc. expanded its ANA testing portfolio in the Asia-Pacific region with the introduction of a new multiplex assay system, offering comprehensive autoantibody profiling for more precise disease diagnosis. This launch aligns with the company’s strategy to strengthen its market presence in the rapidly growing Asia-Pacific diagnostic sector
- In December 2024, MBL (Medical & Biological Laboratories Co., Ltd.) introduced its latest line of diagnostic reagents for ANA testing in the Asia-Pacific market. These reagents are designed to provide highly specific and accurate results, supporting early diagnosis and effective disease management for autoimmune disorders such as systemic lupus erythematosus (SLE) and rheumatoid arthritis
